Since interleukin 1β plays a central role in the pathogenesis of the disease, therapy typically targets this cytokine in the form of monoclonal antibodies (such as canakinumab), binding proteins/traps (such as rilonacept), or interleukin 1 receptor antagonists (such as anakinra). These therapies are generally effective in alleviating symptoms and substantially reducing levels of inflammatory indices. Case reports suggest that thalidomide and the anti-IL-6 receptor antibody tocilizumab may also be effective.
Cryopyrin-associated periodic syndrome
Hereditary angioedema
Antisynthetase syndrome
Mixed connective tissue disease
IgA vasculitis
TNF receptor associated periodic syndrome
Auto-brewery syndrome
Familial Mediterranean fever